Volume 1, Issue 3 (September 2015)                   mazums-pbr 2015, 1(3): 1-10 | Back to browse issues page

DOI: 10.18869/acadpub.pbr.1.3.1

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Reddy H, Gopinath C, Saleem Thattakudian Sheikuduman M. Dabigatran etexilate - A novel oral anticoagulant for bleeding complications. mazums-pbr. 2015; 1 (3) :1-10
URL: http://pbr.mazums.ac.ir/article-1-68-en.html

Department of Pharmacology and Pharmacy Practice, Annamacharya College of Pharmacy, Rajampet, India
Abstract:   (1534 Views)

Thromboembolic disease is a common cause of morbidity and mortality. Thrombin plays a key role in thrombotic events and thrombin inhibition represents a therapeutic event for thromboembolic events and has been identified as a target of therapy of its pivotal role in coagulation process. Anticoagulation is a major intervention for the management of arterial and venous thromboembolic events. Dabigatran etexilate is an orally effective anti-thrombin drug, several animal and human trials were conformed the efficacy of this drug in reduction of major bleeding in related to acute coronary syndrome, knee replacement surgery and venous thromboembolism conditions. The therapeutic use of this drug also shows limited side effects to select the dabigatran as promising therapeutic agent in bleeding complications.

Full-Text [PDF 481 kb]   (738 Downloads)    
Type of Study: Review | Subject: Pharmacology

Add your comments about this article : Your username or Email:
Write the security code in the box

© 2015 All Rights Reserved | Pharmaceutical and Biomedical Research

Designed & Developed by : Yektaweb